Phaseline

Companies › Vicore Pharma

Vicore Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Buloxibutid
Angiotensin II type 2 receptor agonist
AGTR2Phase 2Idiopathic Pulmonary Fibrosis (IPF)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06588686BuloxibutidPhase 2Idiopathic Pulmonary Fibrosis (IPF)RespiratoryMay 2027

Targets

AGTR2 (1)

Companies with the same targets

–

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D SpliSense ReCode Therapeutics Anagram Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.